Abstracts tagged "psoriasis"

Abstract Number: 0822 • ACR Convergence 2021
Local Tolerance of GP2017, an Adalimumab Biosimilar with Low Citrate Concentration Formulation, in Healthy Volunteers and Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Psoriasis
Piotr Wiland¹, Andrew Blauvelt², Lena Lemke³, Oliver von Richter⁴, Alison Balfour⁴, Fabricio Furlan⁴ and Norman Gaylis⁵, ¹Department of Rheumatology and Internal Medicine, Medical University, Wroclaw, Poland, ²Oregon Medical Research Center, Portland, ³Hexal AG (A Sandoz company), Holzkirchen,Germany, Holzkirchen, Germany, ⁴Hexal AG (A Sandoz company), Holzkirchen, Germany, Holzkirchen, Germany, ⁵Arthritis and Rheumatic Disease Specialties, Aventura, FL
Background/Purpose: Adalimumab (ADL) can be self-administered every 2 weeks as a subcutaneous (s.c.) injection in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and psoriasis…
Abstract Number: 0944 • ACR Convergence 2021
A Characterization of the Gut and Cutaneous Microbiome of Monozygotic Twins Discordant for Psoriatic Disease
Julia Manasson¹, Matthew Stapylton², Rhina Medina¹, Rochelle Castillo³, Parvathy Vasudevanpillai Girija¹, Adriana Heguy¹, Carles Ubeda⁴, Mid-Atlantic Twin Registry (MATR)⁵, Jose Clemente² and Jose Scher¹, ¹New York University School of Medicine, New York, NY, ²Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, ³NYU Langone Health, New York, NY, ⁴La Fundación para el Fomento de la Investigación Sanitaria y Biomédica de la Comunitat Valenciana, Valencia, Spain; CIBERESP, Madrid, Spain, ⁵Virginia Commonwealth University, Richmond, VA
Background/Purpose: Psoriasis (PsO) is an inflammatory, immune-mediated skin disorder affecting ~3% of the population worldwide. It is associated with multiple comorbidities, including psoriatic arthritis (PsA),…
Abstract Number: 1781 • ACR Convergence 2021
A Direct-to-Patient PsA Screening Survey for Earlier Identification of At-Risk Psoriasis Patients and Reduction of Physician Burden
Megan Meier¹, Jessica Walsh² and Shaobo Pei³, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT
Background/Purpose: Diagnostic delays are common with psoriatic arthritis (PsA) and contribute to unnecessary impairments in quality of life and function. Screening surveys for identifying at-risk…
Abstract Number: 1784 • ACR Convergence 2021
Characterizing Musculoskeletal Disease Burden in Mild to Moderate Psoriasis Patients Suggestive of Comorbid PsA: Analysis of CorEvitas’ Psoriasis Registry
Alexis Ogdie-Beatty¹, Bruce Strober², Mark Lebwohl³, Angel Cronin⁴, Tin-chi Lin⁴, Hyung-Joo Kang⁴, Nicole Middaugh⁴, Jacqueline O’Brien⁴, Shauna Jardon⁵, Sven Richter⁶, Yuri Klyachkin⁷ and Philip Mease⁸, ¹University of Pennsylvania, Philadelphia, PA, ²Yale University, New Haven, CT, ³Icahn School of Medicine at Mount Sinai, New York, NY, ⁴CorEvitas, LLC, Waltham, MA, ⁵Amgen Inc., Gilbert, AZ, ⁶Amgen Inc., Thousand Oaks, CA, ⁷Amgen Inc., Lexington, KY, ⁸Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: Patients (pts) with mild to moderate psoriasis (PsO) and musculoskeletal disease burden may be diagnosed with PsA upon referral to a rheumatologist. Early intervention…
Abstract Number: 1798 • ACR Convergence 2021
The Transition to Psoriatic Arthritis: What Factors Predict a Shorter Transition from Psoriasis to Psoriatic Arthritis?
Shashank Cheemalavagu¹, Yuxuan Jin² and Elaine Husni², ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Psoriatic arthritis (PsA) occurs in up to 30% of patients with psoriasis (PsO), and usually follows the development of PsO by an average of…
Abstract Number: 0049 • ACR Convergence 2021
CC-99677, a Novel, Selective, Oral MK2 Inhibitor, Sustainably Reduces Pro-inflammatory Cytokine Production and Ameliorates Inflammation in the Mannan-Induced Murine Model of Psoriasis and Psoriatic Arthritis
Rajula Gaur, Kofi Mensah, Jason Stricker, Anastasia Parton, Dorota Cedzik and Francisco Ramírez-Valle, Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Mitogen-activated protein kinase-activated protein kinase-2 (MK2), a direct downstream target of p38, has been identified as a promising candidate for treatment of inflammatory diseases.…
Abstract Number: 0053 • ACR Convergence 2021
Susceptibility Factors for Psoriatic Arthritis Single-cell RNA-Sequencing of Patients with Psoriatic Disease
Ameth Garrido¹, Rohan Machhar², Omar Cruz Correa³, Darshini Ganatra³, Sarah Crome⁴, Joan Wither³, Igor Jurisica⁵ and Dafna Gladman⁶, ¹Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Ajmera Transplant Centre, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease that affects 30% of patients with psoriasis. Thus, early diagnosis of this subgroup is crucial to…
Abstract Number: 0054 • ACR Convergence 2021
TCR Immune Profiling of Patients with Psoriatic Disease
Ameth Garrido¹, Rohan Machhar², Omar Cruz Correa³, Sarah Crome⁴, Joan Wither³, Igor Jurisica⁵ and Dafna Gladman⁶, ¹Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada, ²Krembil Research Institute, University Health Network, Toronto, ON, Canada, ³University Health Network, Toronto, ON, Canada, ⁴Ajmera Transplant Centre, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁵Schroeder Arthritis Institute, Krembil Research Institute, Toronto, ON, Canada, ⁶Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: CD8+ and CD4+ T cell subsets have been implicated in the pathogenesis of psoriatic disease. Here, we explore the T-cell repertoire in psoriatic disease…
Abstract Number: 0140 • ACR Convergence 2021
Therapeutic Management and Clinical Remission in a Specialized Dermatological-Rheumatological Center for Patients with Psoriasis and Psoriatic Arthritis
Jana Ziob¹, Charlotte Behning¹, Peter Brossart², Thomas Bieber¹, Dagmar Wilsmann-Theis³ and Valentin Schäfer⁴, ¹University Hospital Bonn, Bonn, Germany, ²Department of Internal Medicine III, Oncology, Hematology and Rheumatology, University Hospital Bonn, Bonn, Germany, ³Department for Dermatology and Allery, University Hospital Bonn, Bonn, Germany, ⁴Clinic of Internal Medicine III, Oncology, Haematology, Rheumatology and Clinical Immunology, University Hospital Bonn, Bonn, Germany
Background/Purpose: An interdisciplinary approach involving dermatologists and rheumatologists is required for the management of patients with psoriatic arthritis (PsA). The purpose of our study was…
Abstract Number: 0241 • ACR Convergence 2021
Psoriasis Rate Is Increased by the Exposure to TNF Inhibition in Children with JIA
yongdong Zhao¹, Erin Sullivan², Mary Beth Son³ and Timothy Beukelman⁴, ¹University of Washington, Redmond, WA, ²Seattle Children's Research Institute, Seattle, WA, ³Boston Children's Hospital, Brookline, MA, ⁴University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Paradoxical psoriasis has been increasingly reported in adults after exposure to tumor necrosis factor inhibitors (TNFi). Systematic studies in the pediatric population are lacking.…
Abstract Number: 136 • 2020 Pediatric Rheumatology Symposium
Prevalence of Paradoxical Psoriasis After Exposure to Tumor Necrosis Factor Inhibitors (TNFi) in Children from a Single Tertiary Center
Sarah Kodama¹, Deepti Gupta ², Erin Sullivan ³ and Yongdong Zhao ⁴, ¹School of Medicine, Virginia Commonwealth University, Richmond, ²Pediatric Dermatology, School of Medicine, University of Washington, Seattle, ³Seattle Children's Research Institute, Seattle, ⁴University of Washington, Seattle
Background/Purpose: Paradoxical psoriasis after exposure to tumor necrosis factor inhibitors (TNFi) has been increasingly reported in the adult population. Systematic studies in pediatric population are…
Abstract Number: L01 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Yinzhu Jin ¹, Hemin Lee ¹, Moa Lee ², Joan Landon ³, Joseph Merola ⁴, Rishi Desai ⁵ and Seoyoung C. Kim¹, ¹Brigham and Women's Hospital and Harvard Medical School, Boston, ²University of North Carolina Chapel Hill, Chapel Hill, North Carolina, ³Brigham and Women's Hospital, Boston, Massachusetts, ⁴Harvard Medical School, Brigham and Women's Hospital, Boston, ⁵Brigham and Women's hospital, Boston
Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…
Abstract Number: 823 • 2019 ACR/ARP Annual Meeting
The Risk of Venous Thromboembolism in Patients with Psoriatic Disease and Rheumatoid Arthritis, a Population-based Study
Lingyi Li¹, Na Lu ¹, Eric Sayre ¹, Hui Xie ², Diane Lacaille ³, John Esdaile ⁴ and J. Antonio Avina-Zubieta ⁵, ¹Arthritis Research Canada, Vancouver, BC, Canada, ²Arthritis Research Canada and Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada and University of British Columbia, Vancouver, BC, Canada, ⁴Arthritis Research Canada and the University of British Columbia, Richmond, BC, Canada, ⁵Arthritis Research Canada and the University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Venous thromboembolism (VTE, which includes pulmonary embolism [PE] and deep vein thrombosis [DVT]) is associated with increased morbidity and mortality. Previous studies have shown…
Abstract Number: 2463 • 2019 ACR/ARP Annual Meeting
Body Composition and Fat Distribution in Patients with Psoriasis or Psoriatic Arthritis
Eric Toussirot¹, Francois Aubin ¹, maxime Desmarets ¹, Daniel WENDLING ², benoit Augé ³, jerome Gillard ⁴, olivier messica ⁴, Xavier Guillot ¹, caroline Laheurte ⁵, elisabeth monnet ¹ and gilles dumoulin ¹, ¹University Hospital, Besancon, France, ²Rheumatology, University Teaching Hospital (CHRU), Besançon, France, ³private office, besancon, France, ⁴Centre Hospitalier, Lons le Saunier, France, ⁵EFS, besancon, France
Background/Purpose: Obesity is a leading comorbidity in both psoriasis (Pso) and psoriatic arthritis (PsA) and is associated with common metabolic complications and increased cardiovascular (CV)…
Abstract Number: 1008 • 2019 ACR/ARP Annual Meeting
C-X-C Motif Chemokine 10 (CXCL10) as a Transcriptomic Biomarker of Psoriatic Arthritis Susceptibility
Fatima Abji¹, Anastasiya Muntyanu ², Remy Pollock ¹, Rohan Machhar ¹, Justine (Yang) Ye ³, Vinod Chandran ⁴ and Dafna Gladman ⁵, ¹Krembil Research Institute, University Health Network, Toronto, Canada, ²University of Toronto, University Health Network, Toronto, Canada, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, Canada, ⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada
Background/Purpose: We previously identified CXCL10, NOTCH2NL, HAT1, and SETD2 as differentially expressed between psoriasis arthritis (PsA) and psoriasis patients without arthritis (PsC). This study aimed…

1
2
3
…
8
Next Page »